Price
No data yet.
Social Signal Score
Revenue
$4.10MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Joseph Hariri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 115
- Beta
- 0.54
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -15.97
Financials
Revenue
$4.10M-20.3%Net Income
$-24.36MEBITDA
$-21.66MFree Cash Flow
$-5.10MEPS (diluted)
$-0.95-617.1%Shares Outstanding (diluted)
25.60M+612.3%Operating Expenses
$18.41MCash & Debt
$6.17MReturn of Capital
$0.00Revenue by Segment (annual)
$26.55MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $26.55M | $-91.80M | $-3.59 |
| 2024 | $54.22M | $-57.89M | $-2.64 |
| 2023 | $22.77M | $-196.29M | $-11.02 |
| 2022 | $17.98M | $14.19M | $1.01 |
| 2021 | $21.34M | $-100.12M | $-7.87 |
| 2020 | $14.28M | $-208.23M | $-113.06 |
| 2019 | $21.15M | $-211.88M | $-88.75 |
| 2018 | $17.55M | $-1.1K | $0.00 |
Valuation
CELUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Negative
Celularity Provides Update Regarding Nasdaq Listing Compliance FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q fo…
View source ↗
Earnings
Tue, Aug 25(date passed)
Typical surprise +42.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Apr 30$-0.95 vs $-1.50beat
- Fri, Nov 14$-0.88 vs $-1.50beat
- Thu, May 8$-0.84 vs $-1.50beat
- Fri, Dec 6$-0.73 vs $-1.40beat
Estimates and results for CELU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CELU officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.